SEHK:2367
SEHK:2367Personal Products

Asian Market Value Stock Picks For Potential Capital Appreciation

As the Asian markets navigate a landscape marked by mixed performances and economic shifts, investors are closely watching for opportunities amid easing U.S.-China trade tensions and Japan's record stock market highs. In this context, identifying undervalued stocks with strong fundamentals can offer potential for capital appreciation, especially as regional economies adapt to evolving global conditions.
SEHK:806
SEHK:806Capital Markets

Asian Penny Stocks To Watch In November 2025

As global markets navigate a landscape marked by mixed performances and significant geopolitical developments, the Asian market is drawing attention with its unique set of opportunities and challenges. Amid this backdrop, penny stocks—often smaller or younger companies—continue to intrigue investors with their potential for value and growth. Despite the term's somewhat outdated nature, these stocks can still offer promising prospects when backed by strong financials, making them worth...
SEHK:1088
SEHK:1088Oil and Gas

China Shenhua Energy (SEHK:1088): Valuation Insights After Dividend Approval and Nine-Month Earnings Update

China Shenhua Energy (SEHK:1088) just approved an interim dividend of RMB 0.98 per share for the first half of 2025, along with reporting a drop in net income over the past nine months. This combination of steady shareholder returns and updated earnings is putting the stock in focus for investors. See our latest analysis for China Shenhua Energy. After announcing a substantial interim dividend and new earnings results, China Shenhua Energy’s stock has gathered real momentum, with a 30.88%...
SEHK:1209
SEHK:1209Real Estate

Does Renewal of Major Related-Party Agreements Change the Bull Case for China Resources Mixc (SEHK:1209)?

On October 29, 2025, CR Mixc Lifestyle announced the renewal and updating of multiple Connected Transactions (CCT) Framework Agreements with China Resources Holdings (CRH) and CR Bank, covering procurement, value-added services, property management, membership operations, and financial services. This comprehensive renewal sets detailed pricing methodologies and governance standards for ongoing related-party transactions, which are central to the company's recurring business and operational...
SEHK:1258
SEHK:1258Metals and Mining

Can Management Changes at China Nonferrous Mining (SEHK:1258) Reshape Its Growth Story?

China Nonferrous Mining Corporation Limited recently announced that Mr. Yaoyu Tan resigned as non-executive director and audit committee member, with Mr. Zhijiang Chen, a senior accountant with extensive financial management experience within the company’s group, appointed as his replacement effective October 28, 2025. In addition, the company released operating results and earnings guidance for the first nine months of 2025, highlighting a significant increase in copper cathode production...
SEHK:2333
SEHK:2333Auto

How Investors May Respond To Great Wall Motor (SEHK:2333) Expanding Dual Inverter Partnership With BorgWarner

On October 30, 2025, BorgWarner announced it will expand its partnership with Great Wall Motor by launching two additional electrified propulsion projects utilizing advanced dual inverter technology, with mass production targeted for 2026. This collaboration provides Great Wall Motor with greater flexibility and efficiency in hybrid and plug-in hybrid development, supporting regulatory compliance and quicker product iterations for the competitive Chinese automotive market. We'll explore how...
SEHK:175
SEHK:175Auto

Is Geely a Bargain After 8% Pullback and Global EV Expansion Headlines?

Wondering if Geely Automobile Holdings is really a bargain or just looks like one? Let’s break down what’s driving its current price and see if there’s a hidden opportunity for investors like you. Geely’s shares have powered ahead with a 24.4% gain so far this year and are up 22.7% over the last 12 months, but have recently pulled back by around 8% in the past month. This might catch the attention of value hunters or raise questions about changing risks. This recent price drop comes on the...
SEHK:2162
SEHK:2162Biotechs

Why Is Keymed Biosciences (SEHK:2162) Drawing Big-Name Support After Stapokibart’s Approval in China?

Goldman Sachs recently initiated coverage on Keymed Biosciences, highlighting the approval of its first commercial product, stapokibart, in China for atopic dermatitis and chronic rhinosinusitis, while expressing confidence in the pipeline asset CM512 for asthma and COPD. This development underscores the growing recognition of Keymed's product pipeline and the confidence major institutions are placing in the company's future prospects. We'll explore how optimism for Keymed's pipeline,...